2,320 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by HighPoint Advisor Group LLC

HighPoint Advisor Group LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,320 shares of the medical equipment provider’s stock, valued at approximately $297,000.

Several other institutional investors have also recently added to or reduced their stakes in ZBH. Grayhawk Investment Strategies Inc. acquired a new position in shares of Zimmer Biomet during the 4th quarter valued at $567,000. B. Riley Wealth Advisors Inc. increased its stake in Zimmer Biomet by 4.3% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 3,414 shares of the medical equipment provider’s stock valued at $416,000 after purchasing an additional 141 shares in the last quarter. Ables Iannone Moore & Associates Inc. acquired a new position in shares of Zimmer Biomet during the fourth quarter valued at about $30,000. Rovin Capital UT ADV boosted its position in shares of Zimmer Biomet by 24.1% during the 4th quarter. Rovin Capital UT ADV now owns 4,015 shares of the medical equipment provider’s stock worth $489,000 after purchasing an additional 779 shares in the last quarter. Finally, Wahed Invest LLC grew its stake in shares of Zimmer Biomet by 5.5% in the 4th quarter. Wahed Invest LLC now owns 3,449 shares of the medical equipment provider’s stock valued at $420,000 after buying an additional 179 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ZBH has been the topic of several recent research reports. Citigroup increased their price target on Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Evercore ISI increased their target price on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. The Goldman Sachs Group initiated coverage on shares of Zimmer Biomet in a research note on Thursday, May 30th. They set a “neutral” rating and a $129.00 price target for the company. Barclays dropped their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research note on Friday, May 31st. Finally, Truist Financial decreased their target price on shares of Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating for the company in a research report on Friday, May 3rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $133.75.

Zimmer Biomet Trading Down 0.4 %

Shares of Zimmer Biomet stock opened at $106.24 on Friday. The firm has a market cap of $21.86 billion, a PE ratio of 23.00, a P/E/G ratio of 1.92 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $147.50. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.80. The stock has a fifty day moving average price of $116.92 and a 200-day moving average price of $121.54.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter last year, the company posted $1.89 earnings per share. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.90%. The ex-dividend date of this dividend is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.